261 related articles for article (PubMed ID: 19668013)
1. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
Adelstein DJ; Rice TW; Rybicki LA; Saxton JP; Videtic GM; Murthy SC; Mason DP; Rodriguez CP; Ives DI
J Thorac Oncol; 2009 Oct; 4(10):1264-9. PubMed ID: 19668013
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity.
Adelstein DJ; Rice TW; Rybicki LA; Saxton JP; Videtic GM; Murthy SC; Zuccaro G; Vargo JJ; Dumot JA; Carroll MA
Am J Clin Oncol; 2007 Apr; 30(2):172-80. PubMed ID: 17414467
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Rodriguez CP; Adelstein DJ; Rice TW; Rybicki LA; Videtic GM; Saxton JP; Murthy SC; Mason DP; Ives DI
J Thorac Oncol; 2010 Feb; 5(2):229-35. PubMed ID: 20009775
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.
McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA
J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
6. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
[TBL] [Abstract][Full Text] [Related]
7. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
8. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G
Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
10. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction.
Posner MC; Gooding WE; Landreneau RJ; Rosenstein MM; Clarke MR; Peterson MS; Lembersky BC
Cancer J Sci Am; 1998; 4(4):237-46. PubMed ID: 9689982
[TBL] [Abstract][Full Text] [Related]
11. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Walsh G; Komaki R; Morris J; Swisher SG; Putnam JB; Lynch PM; Wu TT; Smythe R; Vaporciyan A; Faust J; Cohen DS; Nivers R; Roth JA
Cancer; 2004 Jun; 100(11):2347-54. PubMed ID: 15160337
[TBL] [Abstract][Full Text] [Related]
12. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas.
Wang J; Milton DR; He L; Komaki R; Liao Z; Crane CH; Minsky BD; Thall PF; Lin SH
J Thorac Oncol; 2015 Mar; 10(3):518-26. PubMed ID: 25695222
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Heath EI; Burtness BA; Heitmiller RF; Salem R; Kleinberg L; Knisely JP; Yang SC; Talamini MA; Kaufman HS; Canto MI; Topazian M; Wu TT; Olukayode K; Forastiere AA
J Clin Oncol; 2000 Feb; 18(4):868-76. PubMed ID: 10673530
[TBL] [Abstract][Full Text] [Related]
14. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
Adelstein DJ; Rice TW; Becker M; Larto MA; Kirby TJ; Koka A; Tefft M; Zuccaro G
Cancer; 1997 Sep; 80(6):1011-20. PubMed ID: 9305700
[TBL] [Abstract][Full Text] [Related]
15. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
16. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.
Swisher SG; Moughan J; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
J Thorac Oncol; 2017 Feb; 12(2):368-374. PubMed ID: 27729298
[TBL] [Abstract][Full Text] [Related]
17. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
Dipetrillo T; Suntharalingam M; Ng T; Fontaine J; Horiba N; Oldenburg N; Perez K; Birnbaum A; Battafarano R; Burrows W; Safran H
Am J Clin Oncol; 2012 Feb; 35(1):64-7. PubMed ID: 21297434
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials.
Sohal DP; Rice TW; Rybicki LA; Rodriguez CP; Videtic GM; Saxton JP; Murthy SC; Mason DP; Phillips BE; Tubbs RR; Plesec T; McNamara MJ; Ives DI; Bodmann JW; Adelstein DJ
Dis Esophagus; 2015; 28(6):547-51. PubMed ID: 24849395
[TBL] [Abstract][Full Text] [Related]
20. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
